Tumor-targeting domains for chimeric antigen receptor T cells
K Bezverbnaya, A Mathews, J Sidhu, CW Helsen… - …, 2017 - Taylor & Francis
Immunotherapy with chimeric antigen receptor (CAR) T cells has been advancing steadily in
clinical trials. Since the ability of engineered T cells to recognize intended tumor-associated …
clinical trials. Since the ability of engineered T cells to recognize intended tumor-associated …